What Is a Neurogenic Tumor and Where Do They Occur?

A neurogenic tumor is any growth that arises from the cells of the nervous system or its supporting structures, including the protective sheaths that wrap around nerves, the specialized cells of the sympathetic chain, and hormone-producing paraganglia scattered throughout the body. These tumors range from completely benign lumps that sit quietly for years to aggressive cancers that spread, and they can show up almost anywhere a nerve runs. That “almost anywhere” quality is what makes them simultaneously common in certain body compartments and surprisingly easy to overlook.

The Three Families of Neurogenic Tumors

Rather than being a single disease, “neurogenic tumor” is an umbrella term covering at least three broad families, each defined by the cell type that gives rise to the growth. Understanding which family a tumor belongs to matters because it shapes the prognosis, the expected behavior, and the treatment plan.

• Nerve sheath tumors: These grow from the cells that insulate and support nerve fibers. The most common types are schwannomas (which arise from Schwann cells) and neurofibromas (which involve a mix of cell types within the nerve). Malignant peripheral nerve sheath tumors, or MPNSTs, are the dangerous end of this spectrum.
• Ganglion cell tumors: These develop from the cells of the sympathetic nervous system. The spectrum runs from ganglioneuromas, which are fully mature and benign, through ganglioneuroblastomas with mixed maturity, to neuroblastomas, the most immature and aggressive form.
• Paraganglionic tumors: These include pheochromocytomas and paragangliomas, which arise from hormone-producing clusters of cells associated with the autonomic nervous system. Some of these tumors actively secrete catecholamines, causing dramatic symptoms like episodes of high blood pressure, rapid heartbeat, and sweating.

This classification scheme has held up for decades and remains the standard framework pathologists use when they encounter a growth of nervous-system origin.¹

Where They Turn Up Most Often

Neurogenic tumors follow nerves, and nerves go everywhere. Still, certain body regions harbor a disproportionate share of these growths, largely because of how dense nerve tissue is in those areas.

The Chest

The posterior mediastinum, the deep compartment of the chest that sits alongside the spine, is the single most common site for neurogenic tumors in adults. Schwannomas are especially frequent here, growing along the intercostal nerves or the sympathetic chain that runs parallel to the vertebral bodies. But nerve sheath tumors are not confined to the back of the chest; they have been reported in all compartments of the mediastinum.² Many of these are discovered incidentally on a chest X-ray or CT scan done for something else entirely, because they tend to grow slowly and may not cause symptoms until they are quite large.

The Abdomen and Pelvis

The retroperitoneum, a space behind the abdominal cavity that houses the kidneys, major blood vessels, and a dense network of autonomic nerves, is the second major hotspot. Schwannomas in this location are considered uncommon, yet they still account for a meaningful share of retroperitoneal masses. Most tumors under five centimeters are found by accident during imaging for unrelated complaints. When they do produce symptoms, those tend to be vague: dull back pain, digestive discomfort, or urinary changes caused by the tumor pressing on neighboring organs.³ One study of retroperitoneal schwannomas found that only about a third of patients had any clinical symptoms at all; the rest were picked up incidentally on imaging.⁴

Ganglion cell tumors also favor the abdomen, particularly the adrenal glands and the sympathetic ganglia along the spine. In children, these retroperitoneal locations are where neuroblastomas most commonly appear.

The Head and Neck

Schwannomas can develop along any of the cranial and cervical nerves, including the vagus nerve, the brachial plexus, the sympathetic chain, and the lingual nerve.⁵ A schwannoma of the cervical vagus nerve is rare but well-documented; it typically presents as a slow-growing, painless lump in the neck, most often in men between roughly their thirties and sixties.⁶ Paragangliomas also show up in the head and neck, particularly at the carotid body, a tiny oxygen-sensing cluster near the carotid artery bifurcation.

The Spine

Spinal schwannomas are a classic example of a “dumbbell” tumor, named for their shape when the growth extends through a neural foramen, the small opening where a nerve root exits the spine, creating a mass on either side connected by a narrow waist. Cervical dumbbell schwannomas are especially complex to manage surgically because of the delicate anatomy involved.⁷ Spinal neurogenic tumors can cause radicular pain, numbness, or weakness in the limbs, mimicking a herniated disc in their early stages.

How Neurogenic Tumors Behave

Most neurogenic tumors are benign and slow-growing. A schwannoma may sit on a nerve for years, gradually enlarging without invading the nerve itself. It pushes fibers aside rather than infiltrating them, which is one reason surgical removal can often preserve nerve function. Even benign tumors, however, cause trouble if they grow large enough to compress surrounding structures. Depending on location, that compression can produce pain, tingling, weakness, or dysfunction of whatever organ sits nearby.

The ganglion cell family offers a clear illustration of how maturity determines behavior. Ganglioneuromas are composed of fully mature nerve cells and stroma. They are essentially benign, and patients with favorable-histology tumors in this spectrum, including ganglioneuromas and intermixed ganglioneuroblastomas, had no tumor-related deaths in a large cooperative group study.⁸ Neuroblastoma sits at the opposite end: it is the most immature form, arises primarily in young children (median age around two years), and behaves aggressively.⁹

Paraganglionic tumors add another layer of complexity because some of them are “functional,” meaning they actively pump out hormones. Pheochromocytomas and paragangliomas can secrete catecholamines such as norepinephrine and epinephrine, and the pattern of secretion actually differs between those that have spread and those that have not. Metastatic tumors tend to secrete less epinephrine, while non-metastatic ones produce more.¹⁰ Recognizing a functional paraganglioma before surgery is critical, because operating on one without proper preoperative preparation can trigger a life-threatening blood pressure crisis.

The Neuroblastoma Connection in Children

Neuroblastoma deserves special attention because it is one of the most common solid tumors in children and it is thought to originate from precursor cells of the sympathetic nervous system during embryonic development. Research into how the neural crest, the group of embryonic cells that gives rise to sympathetic neurons and many other tissues, normally develops has been central to understanding what goes wrong in neuroblastoma.¹¹ In a sense, neuroblastoma is a failure of normal maturation: the precursor cells get stuck in an immature state and keep dividing instead of maturing into functioning nerve cells.

Ganglioneuromas and ganglioneuroblastomas appear in older children, with a median age of about seven years, and their prognosis is far better. The biology here is essentially a maturation gradient, and where a specific tumor falls on that gradient is one of the strongest predictors of outcome.⁹

When Neurogenic Tumors Become Malignant

The malignant counterpart of benign nerve sheath tumors is the MPNST, and it is among the more feared soft-tissue sarcomas. The biggest risk factor for developing one is having a pre-existing benign plexiform neurofibroma, particularly in the setting of neurofibromatosis type 1. Prior radiation treatment and certain large gene deletions also raise the risk. At the molecular level, the progression from a benign neurofibroma to a frankly malignant MPNST involves a stepwise accumulation of additional genetic hits, including loss of tumor-suppressor genes like CDKN2A, TP53, and alterations in SUZ12.¹²

In a pediatric cohort, about 43% of MPNST cases in patients with neurofibromatosis type 1 arose from a pre-existing plexiform neurofibroma.¹³ This means that not every MPNST comes from a preexisting benign growth, but the connection is strong enough that patients with known plexiform neurofibromas need regular surveillance.

Surgery after MPNST carries its own burden. Over 80% of surveyed MPNST survivors reported neuropathic pain following tumor removal, and that pain significantly affected their quality of life.¹⁴ This underscores the need for pain management strategies and, when possible, nerve-sparing surgical techniques.

The Role of Genetic Syndromes

Several inherited conditions predispose people to developing neurogenic tumors, and these syndromes account for a disproportionate share of multiple or recurrent tumors.

Neurofibromatosis type 1 is one of the most common genetic disorders. It is caused by mutations in the NF1 gene, which encodes a protein called neurofibromin. That protein normally acts as a brake on a cell-growth signaling pathway. When the brake fails, cells grow more readily, leading to the hallmark neurofibromas and raising the risk of malignant transformation.¹⁵ Tumor formation typically requires a “second hit,” meaning that the remaining normal copy of the NF1 gene also has to be lost or disabled in the cell that becomes the tumor’s starting point.¹⁶

Schwannomatosis is a separate group of conditions caused by mutations in genes on chromosome 22, including NF2, LZTR1, and SMARCB1. All three predispose people to develop multiple schwannomas, but the exact pattern of tumor locations and long-term outlook differs depending on which gene is affected.¹⁷ Patients with schwannomatosis often deal with chronic pain as their primary symptom, even when the tumors themselves are small.

Treatment Approaches

Surgery remains the cornerstone of treatment for most neurogenic tumors. For benign schwannomas and neurofibromas, the goal is to remove the tumor while preserving the nerve it grew on. Tumor enucleation, where the growth is carefully shelled out from within its capsule, is the preferred technique for nerve preservation, though it does not guarantee completely intact nerve function afterward.¹⁸ In a study of patients without neurofibromatosis, complete removal was achievable in the majority of cases, and patients with preoperative nerve deficits generally improved after surgery without worsening in those who had intact function before the operation.¹⁹

For tumors that cannot be safely removed, particularly the large plexiform neurofibromas associated with neurofibromatosis type 1 that wrap around vital structures, drug therapy has made meaningful progress. Selumetinib, a drug that blocks a key step in the overactive growth-signaling pathway, showed tumor shrinkage in a majority of treated patients. In one trial of adults with inoperable plexiform neurofibromas, about two-thirds of participants had an objective response, with a median volume decrease of roughly 24%.²⁰ A combined pediatric and adult study found even higher response rates, with over 90% of per-protocol patients achieving at least a 20% volume reduction.²¹ Selumetinib also reduced spinal neurofibroma burden in patients carrying these tumors.²² The drug does not cure the tumors, but by holding them in check it can relieve pain and prevent further compression of surrounding tissue.

Hybrid Tumors and Diagnostic Gray Zones

Pathology is not always tidy, and neurogenic tumors sometimes refuse to fit neatly into one category. Hybrid peripheral nerve sheath tumors contain features of more than one type, for example, regions that look like a schwannoma interspersed with regions that look like a neurofibroma. These hybrids were first formally described decades ago, when researchers noted nine lesions with predominant neurofibroma features but distinct nodular zones of classic schwannoma differentiation.²³ Since then, the category has expanded to include schwannoma/perineurioma hybrids and neurofibroma/perineurioma hybrids, typically arising in the skin of the extremities and trunk.²⁴

Recent molecular work has started to explain these mixed appearances. Novel gene fusions and recurrent mutations have been identified in certain hybrid tumors, suggesting they are not just diagnostic oddities but reflect distinct biological pathways.²⁵ In one unusual case, a hybrid neurofibroma/schwannoma of the ulnar nerve was found to harbor a deposit of metastatic thyroid cancer, a genuine tumor-within-a-tumor scenario that initially confused imaging and biopsy results.²⁶ Cases like these are extreme rarities, but they illustrate why pathologists sometimes struggle with the “what is it?” question and why molecular profiling is becoming more routine.

Emerging Blood-Based Detection for Malignant Transformation

One of the hardest clinical challenges with neurogenic tumors, especially in patients with neurofibromatosis, is figuring out whether a growing lump is just a benign neurofibroma getting bigger or an MPNST forming. Imaging alone often cannot make that distinction reliably, and biopsy can be impractical when a patient has dozens of neurofibromas. Researchers are now exploring liquid biopsy approaches that analyze fragments of tumor DNA circulating in the blood. One study found that genome-wide analysis of abnormal chromosome numbers in circulating cell-free DNA could detect MPNST with about 50% sensitivity and 97% specificity when sub-chromosomal copy number changes were included.²⁷ A separate research group found that analysis of DNA fragmentation patterns in blood samples could distinguish malignant from benign nerve tumors, and they believe these findings could eventually lead to routine screening assays for patients at high risk.²⁸ The sensitivity is still too low for a definitive standalone test, but as a screening filter to decide who needs urgent biopsy, the technology is promising.